Daix (France), Long Island City (New York, United States), December 20, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of small molecules administered by oral route for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical need, today announces the randomization of the first patient in China in the global clinical study of Phase III NATiV3 and provides an update on its clinical development program.